Asia Pacific Prophylaxis Of Organ Rejection Market
حجم السوق بالمليار دولار أمريكي
CAGR :
% 
 فترة التنبؤ |
2022 –2029 |
 حجم السوق (السنة الأساسية) |
USD 599.21 Million |
 حجم السوق (سنة التنبؤ) |
USD 943.85 Million |
 CAGR |
% |
| Major Markets Players |
>سوق الوقاية من رفض الأعضاء في منطقة آسيا والمحيط الهادئ حسب السبب (التعرض الوبائي، الوقاية من مضادات البكتيريا، الوقاية من مسببات الأمراض الأخرى وغيرها)، العلاج (مثبطات المناعة للمرضى الخارجيين، مثبطات المناعة للمرضى الداخليين وغيرها)، طريق الإدارة (عن طريق الفم، عن طريق الوريد)، حسب العضو (الكلى، الكبد، القلب، الرئة وغيرها)، نوع المريض (الأطفال، البالغين)، المستخدم النهائي (المستشفيات، العيادات المنزلية للرعاية الصحية وغيرها)، قناة التوزيع (العطاء المباشر، مخازن الصيدليات وغيرها)، حسب البلد اتجاهات صناعة منطقة آسيا والمحيط الهادئ (اليابان والصين وأستراليا وكوريا الجنوبية والهند وسنغافورة وتايلاند وإندونيسيا وماليزيا والفلبين وبقية دول آسيا والمحيط الهادئ) والتوقعات حتى عام 2029.
تحليل السوق والرؤى : سوق الوقاية من رفض الأعضاء في منطقة آسيا والمحيط الهادئ
من المتوقع أن يكتسب سوق الوقاية من رفض الأعضاء في منطقة آسيا والمحيط الهادئ نموًا في السوق في الفترة المتوقعة من 2022 إلى 2029. تحلل شركة Data Bridge Market Research أن السوق ينمو بمعدل نمو سنوي مركب بنسبة 6.0٪ في الفترة المتوقعة من 2022 إلى 2029 ومن المتوقع أن يصل إلى 943.85 مليون دولار أمريكي بحلول عام 2029 من 599.21 مليون دولار أمريكي في عام 2021. من المرجح أن يكون الانتشار المتزايد لزراعة الأعضاء والزيادة في استخدام مثبطات المناعة من المحركات الرئيسية التي تدفع الطلب على السوق في الفترة المتوقعة.
إن مصطلح الوقاية يعني العلاج المعطى أو الإجراء المتخذ لمنع المرض. إن الوقاية من رفض العضو تشير إلى منع رفض العضو باستخدام الأدوية. يجب على المرضى الذين يخضعون لعملية زرع أن يتبعوا نظامًا مثبطًا للمناعة للوقاية من الرفض للمساعدة في ضمان بقاء الطعم. إن رفض عملية الزرع هي عملية يتم فيها تطبيق الوقاية الحالية للرفض باستخدام مثبطات الكالسينيورين ومثبطات mTOR وعوامل مضادة للأيض والكورتيكوستيرويدات. تعمل عوامل العلاج على تحسين العواقب القصيرة الأجل لعملية زرع الأعضاء، ولكن هناك بعض التحسينات. يجب على المرضى المتلقين الذين خضعوا لعملية زرع أعضاء صلبة تناول أدوية مضادة للرفض. وذلك لأن جهاز المناعة من شأنه أن يدمر العضو المزروع.
العوامل الدافعة المسؤولة عن نمو سوق الوقاية من رفض الأعضاء في منطقة آسيا والمحيط الهادئ هي زيادة انتشار زراعة الأعضاء، وزيادة العمليات الجراحية، وزيادة عدد المتلقين وإطلاق المنتجات. ومع ذلك، فإن العوامل التي من المتوقع أن تقيد السوق هي ارتفاع تكلفة إجراء عملية الزرع، ونقص الوعي بزراعة الأعضاء والمخاطر التي ينطوي عليها تلقي المريض للعضو المزروع.
On the other hand, strategic initiatives by market players, rise in research and developments and use of immunosuppressant may act as an opportunity for the growth of the Asia-Pacific prophylaxis of organ rejection market. The need for skilled expertise and the regulatory approval may create challenges for the Asia-Pacific prophylaxis of organ rejection market. There are recent developments related to the Asia-Pacific prophylaxis of organ rejection market.
Asia-Pacific prophylaxis of organ rejection market report provides details of market share, new developments, and impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Asia- Pacific Prophylaxis of Organ Rejection Market Scope and Market Size
Asia- Pacific prophylaxis of organ rejection market is segmented on the basis of cause, treatment route of administration, organ, end user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
The Asia-Pacific prophylaxis of organ rejection market is categorized into seven segments: cause, treatment, route of administration, organ, patient type, end user and distribution channel.
- On the basis of cause, the Asia-Pacific prophylaxis of organ rejection market is segmented into epidemiologic exposure, antibacterial prophylaxis, prophylaxis against other pathogens and others. In 2022, the epidemiologic exposure segment is expected to dominate the Asia-Pacific prophylaxis of organ rejection market due to availability of direct information and presence of pathogens related to prophylaxis of organ rejection in China
- On the basis of treatment, the Asia-Pacific prophylaxis of organ rejection market is segmented into outpatient immunosuppressant, inpatient immunosuppressant and others. In 2022, the outpatient immunosuppressant segment is expected to dominate the Asia-Pacific prophylaxis of organ rejection market, since it can achieve the sustained and specific immune response against damaged cells and avialability of cyclosporine in the Shanghai.
- On the basis of route of administration, the Asia-Pacific prophylaxis of organ rejection market is segmented into oral and intravenous. In 2022, the oral segment is expected to dominate the Asia-Pacific prophylaxis of organ rejection due to increased availability and intake of oral tablets and capsules.
- On the basis of organ, the Asia-Pacific prophylaxis of organ rejection market is segmented into kidney, liver, heart, lung and others. In 2022, the kidney segment is expected to dominate the Asia-Pacific prophylaxis of organ rejection due to increased incidence of kidney failure and presence of reimbursement policies such as Medicare, for the recipient’s insurance.
- On the basis of patient type, the Asia-Pacific prophylaxis of organ rejection market is segmented into pediatric and adults. In 2022, the adults segment is expected to dominate the Asia-Pacific prophylaxis of organ rejection market, due to increased prevalence of chronic diseases and genetic conditions of the adult patients, weak immune system in adults and waiting list of adult recipients more than the waiting list of children and women in New Mexico and the U.S.
- On the basis of end user, the Asia-Pacific prophylaxis of organ rejection market is segmented into hospitals, clinics, home healthcare and others. In 2022, the hospitals segment is expected to dominate the Asia-Pacific prophylaxis of organ rejection market due to rise in medical care and collaboration with other hospitals in Asia-Pacific for delivery of the donor organs to the recipient patients are predicted to dominate the market.
- On the basis of distribution channel, the Asia-Pacific prophylaxis of organ rejection market is segmented into direct tenders, pharmacy stores and others. In 2022, the direct tenders segment is expected to dominate the Asia-Pacific prophylaxis of organ rejection market due to surge in demand of outpatient immunosuppressant by pharmaceutical companies and guaranteed payment, are predicted to dominate the market.
Asia-Pacific Prophylaxis of Organ Rejection Market Country Level Analysis
Asia- Pacific prophylaxis of organ rejection market is segmented on the basis of cause, treatment route of administration, organ, end user and distribution channel.
The countries covered in the prophylaxis of organ rejection market report are China, Japan, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines and Rest of Asia-Pacific.
Asia-Pacific is expected to grow with the highest CAGR in the forecasted periods as in the Asia-Pacific’s countries demand for prophylaxis of organ rejection product is increasing very rapidly with the urbanization and laboratory automation. China is expected to dominate in the market in the Asia-Pacific market. China is one of the leading countries to inculcate prophylaxis of organ rejection market, due to rise in patient population, waiting for organ transplantation and rise in surgical procedures.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Asia Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Growth Potential for Prophylaxis of Organ Rejection in Emerging Economies and the Strategic Initiatives by Market Players are Creating New Opportunities in the Asia-Pacific Prophylaxis of Organ Rejection Market
Asia Pacific Prophylaxis of organ rejectionMarket also provides you with detailed market analysis for every country growth in particular industry with prophylaxis of organ rejection sales, impact of advancement in the prophylaxis of organ rejection and changes in regulatory scenarios with their support for the prophylaxis of organ rejection market. The data is available for historic period 2020 to 2021.
Competitive Landscape and Asia Pacific Prophylaxis of organ rejection Market Share Analysis
Asia Pacific prophylaxis of organ rejection market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to prophylaxis of organ rejection market.
The major companies providing the Asia- Pacific prophylaxis of organ rejection are Concord Biotech, Panacea Biotec, WOCKHARDT, Astellas Pharma Inc, Novartis AG, Bristol-Myers Squibb Company, Dr Reddy’s Laboratories, Ltd, Viatris Inc, Strides Pharma Science Limited, Glenmark, Biocon, Pfizer Inc, Mayne Pharma Group Limited, Hikma Pharmaceuticals PLC, AbbVie Inc, Apotex Inc, Pharmaceuticals LLC, Zydus Pharmaceuticals, Inc., ZHEJIANG HISUN PHARMACEUTICAL Co., LTD., CSL Behring among others.
DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The strategic initiatives by market players along with new technological advancements for prophylaxis of organ rejection are bridging the gap for chronic wounds treatment.
For instance,
- في سبتمبر 2021، أوقفت شركة نوفارتس أيه جي استخدام دراسة CIRRUS-1 لـ CFZ533 (iscalimab) في مرضى زراعة الكلى. وأشار التحليل إلى أن العلاج القائم على CFZ533 (iscalimab) أقل فعالية مقارنة بالعلاج القائم على التاكروليموس في منع رفض العضو لدى المرضى الذين يتلقون عملية زرع الكلى. سيؤدي إيقاف التجربة السريرية إلى تأخير الموافقة على الدواء.
يعمل التعاون والمشاريع المشتركة والاستراتيجيات الأخرى من قبل اللاعب في السوق على تعزيز سوق الشركة في سوق الوقاية من رفض الأعضاء مما يوفر أيضًا فائدة للمنظمة لتحسين عرضها لسوق الوقاية من رفض الأعضاء.
SKU-
احصل على إمكانية الوصول عبر الإنترنت إلى التقرير الخاص بأول سحابة استخبارات سوقية في العالم
- لوحة معلومات تحليل البيانات التفاعلية
- لوحة معلومات تحليل الشركة للفرص ذات إمكانات النمو العالية
- إمكانية وصول محلل الأبحاث للتخصيص والاستعلامات
- تحليل المنافسين باستخدام لوحة معلومات تفاعلية
- آخر الأخبار والتحديثات وتحليل الاتجاهات
- استغل قوة تحليل المعايير لتتبع المنافسين بشكل شامل
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 BY CAUSE SEGMENT LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END USER COVERAGE GRID
2.11 SECONDARY SOURCES
3 EXECUTIVE SUMMARY
4 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION: EPIDEMIOLOGY SNAPSHOT
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 RISE IN PREVALENCE OF ORGAN TRANSPLANTATIONS
5.1.2 RISE IN CHRONIC DISEASES
5.1.3 RISE IN CLINICAL TRIALS
5.1.4 RISE IN RECIPIENT PATIENTS
5.1.5 PRODUCT APPROVALS
5.2 RESTRAINTS
5.2.1 RISE IN COST OF TRANSPLANTATION PROCEDURE
5.2.2 LACK OF AWARENESS ABOUT ORGAN TRANSPLANTATION
5.2.3 RISKS INCLUDED WITH THE PATIENT RECEIVES TRANSPLANTED ORGAN
5.2.4 ETHICAL ISSUES RELATED TO ORGAN TRANSPLANTATION
5.3 OPPORTUNITIES
5.3.1 RISE IN RESEARCH AND DEVELOPMENTS
5.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
5.3.3 RISE IN USE OF IMMUNOSUPPRESSANT
5.4 CHALLENGES
5.4.1 SHORTAGE OF SKILLED PROFESSIONALS REQUIRED FOR THE USE OF PROPHYLAXIS OF ORGAN REJECTION
5.4.2 STRINGENT REGULATIONS
6 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE
6.1 OVERVIEW
6.2 EPIDEMIOLOGIC EXPOSURE
6.2.1 HOSPITAL EXPOSURE
6.2.2 COMMUNITY EXPOSURE
6.3 ANTIBACTERIAL PROPHYLAXIS
6.3.1 POST-TRANSPLANT PROPHYLAXIS
6.3.2 PERIOPERATIVE ANTIBACTERIAL PROPHYLAXIS
6.4 PROPHYLAXIS AGAINST OTHER PATHOGENS
6.5 OTHERS
7 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT
7.1 OVERVIEW
7.2 OUTPATIENT IMMUNOSUPPRESSANT
7.2.1 CALCINEURIN INHIBITORS
7.2.1.1 CYCLOSPORINE
7.2.1.2 TACROLIMUS
7.2.1.2.1 IMMEDIATE RELEASE
7.2.1.2.2 EXTENDED RELEASE
7.2.2 CORTICOSTEROIDS
7.2.2.1 METHYLPREDNISOLONE
7.2.2.2 PREDNISONE
7.2.2.3 OTHERS
7.2.3 MYCOPHENOLIC ACIDS
7.2.3.1 MYCOPHENOLATE MOFETIL
7.2.3.2 MYCOPHENOLATE SODIUM
7.2.4 MTOR INHIBITORS
7.2.4.1 SIROLIMUS
7.2.4.2 EVEROLIMUS
7.2.5 AZATHIOPRINE
7.2.6 OTHERS
7.3 INPATIENT IMMUNOSUPPRESSANT
7.3.1 BELATACEPT
7.3.2 BASILIXIMAB
7.3.3 OTHERS
7.4 OTHERS
7.4.1 ERYTHROPOIESIS-STIMULATING AGENTS
7.4.1.1 ERYTHROPOIETIN
7.4.1.2 DARBEPOETIN
7.4.2 ANTI-VIRAL AGENTS
7.4.2.1 VALGANCICLOVIR
7.4.2.2 LAMIVUDINE
7.4.2.3 ADEFOVIR
7.4.2.4 OTHERS
7.4.3 OTHERS
8 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION
8.1 OVERVIEW
8.2 ORAL
8.2.1 TABLET
8.2.1.1 IMMEDIATE RELEASE
8.2.1.2 EXTENDED-RELEASE
8.2.2 ORAL SOLUTION
8.2.3 OTHERS
8.3 INTRAVENOUS
9 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN
9.1 OVERVIEW
9.2 KIDNEY
9.3 LIVER
9.4 HEART
9.5 LUNG
9.6 OTHERS
10 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE
10.1 OVERVIEW
10.2 ADULTS
10.3 PEDIATRIC
11 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.3 CLINICS
11.4 HOME HEALTHCARE
11.5 OTHERS
12 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDERS
12.3 PHARMACY STORES
12.3.1 HOSPITAL PHARMACY
12.3.2 RETAIL PHARMACY
12.3.3 ONLINE PHARMACY
12.4 OTHERS
13 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION
13.1 ASIA-PACIFIC
13.1.1 CHINA
13.1.2 JAPAN
13.1.3 SOUTH KOREA
13.1.4 INDIA
13.1.5 AUSTRALIA
13.1.6 THAILAND
13.1.7 MALAYSIA
13.1.8 PHILIPPINES
13.1.9 SINGAPORE
13.1.10 INDONESIA
13.1.11 VIETNAM
13.1.12 REST OF ASIA-PACIFIC
14 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC
15 QUESTIONNAIRE
16 RELATED REPORTS
List of Table
TABLE 1 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 2 ASIA PACIFIC EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 ASIA PACIFIC EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 4 ASIA PACIFIC ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 ASIA PACIFIC ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 6 ASIA PACIFIC PROPHYLAXIS AGAINST OTHER PATHOGENS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 ASIA PACIFIC OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 9 ASIA PACIFIC OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 ASIA PACIFIC OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 11 ASIA PACIFIC CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 12 ASIA PACIFIC TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 13 ASIA PACIFIC CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 14 ASIA PACIFIC MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 15 ASIA PACIFIC MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 16 ASIA PACIFIC INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 ASIA PACIFIC INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 18 ASIA PACIFIC OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 ASIA PACIFIC OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 20 ASIA PACIFIC ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 21 ASIA PACIFIC ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 22 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 23 ASIA PACIFIC ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 ASIA PACIFIC ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 25 ASIA PACIFIC TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 26 ASIA PACIFIC INTRAVENOUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)
TABLE 28 ASIA PACIFIC KIDNEY IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 ASIA PACIFIC LIVER IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 ASIA PACIFIC HEART IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 ASIA PACIFIC LUNG IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 ASIA PACIFIC OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 34 ASIA PACIFIC ADULTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 ASIA PACIFIC PEDIATRIC IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 37 ASIA PACIFIC HOSPITALS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 38 ASIA PACIFIC CLINICS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 39 ASIA PACIFIC HOME HEALTHCARE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 40 ASIA PACIFIC OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 41 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 42 ASIA PACIFIC DIRECT TENDERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 43 ASIA PACIFIC PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 44 ASIA PACIFIC PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 45 ASIA PACIFIC OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 46 ASIA-PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 47 ASIA-PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 48 ASIA-PACIFIC EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 49 ASIA-PACIFIC ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 50 ASIA-PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 51 ASIA-PACIFIC OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 52 ASIA-PACIFIC CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 53 ASIA-PACIFIC TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 54 ASIA-PACIFIC MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 55 ASIA-PACIFIC MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 56 ASIA-PACIFIC CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 57 ASIA-PACIFIC INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 58 ASIA-PACIFIC OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 59 ASIA-PACIFIC ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 60 ASIA-PACIFIC ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 61 ASIA-PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 62 ASIA-PACIFIC ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 63 ASIA-PACIFIC TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 64 ASIA-PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)
TABLE 65 ASIA-PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 66 ASIA-PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 67 ASIA-PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 68 ASIA-PACIFIC PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 69 CHINA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 70 CHINA EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 71 CHINA ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 72 CHINA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 73 CHINA OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 74 CHINA CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 75 CHINA TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 76 CHINA MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 77 CHINA MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 78 CHINA CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 79 CHINA INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 80 CHINA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 81 CHINA ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 82 CHINA ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 83 CHINA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 84 CHINA ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 85 CHINA TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 86 CHINA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)
TABLE 87 CHINA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 88 CHINA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 89 CHINA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 90 CHINA PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 91 JAPAN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 92 JAPAN EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 93 JAPAN ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 94 JAPAN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 95 JAPAN OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 96 JAPAN CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 97 JAPAN TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 98 JAPAN MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 99 JAPAN MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 100 JAPAN CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 101 JAPAN INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 102 JAPAN OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 103 JAPAN ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 104 JAPAN ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 105 JAPAN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 106 JAPAN ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 107 JAPAN TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 108 JAPAN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)
TABLE 109 JAPAN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 110 JAPAN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 111 JAPAN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 112 JAPAN PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 113 SOUTH KOREA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 114 SOUTH KOREA EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 115 SOUTH KOREA ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 116 SOUTH KOREA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 117 SOUTH KOREA OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 118 SOUTH KOREA CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 119 SOUTH KOREA TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 120 SOUTH KOREA MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 121 SOUTH KOREA MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 122 SOUTH KOREA CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 123 SOUTH KOREA INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 124 SOUTH KOREA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 125 SOUTH KOREA ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 126 SOUTH KOREA ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 127 SOUTH KOREA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 128 SOUTH KOREA ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 129 SOUTH KOREA TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 130 SOUTH KOREA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)
TABLE 131 SOUTH KOREA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 132 SOUTH KOREA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 133 SOUTH KOREA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 134 SOUTH KOREA PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 135 INDIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 136 INDIA EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 137 INDIA ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 138 INDIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 139 INDIA OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 140 INDIA CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 141 INDIA TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 142 INDIA MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 143 INDIA MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 144 INDIA CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 145 INDIA INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 146 INDIA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 147 INDIA ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 148 INDIA ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 149 INDIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 150 INDIA ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 151 INDIA TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 152 INDIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)
TABLE 153 INDIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 154 INDIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 155 INDIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 156 INDIA PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 157 AUSTRALIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 158 AUSTRALIA EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 159 AUSTRALIA ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 160 AUSTRALIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 161 AUSTRALIA OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 162 AUSTRALIA CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 163 AUSTRALIA TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 164 AUSTRALIA MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 165 AUSTRALIA MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 166 AUSTRALIA CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 167 AUSTRALIA INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 168 AUSTRALIA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 169 AUSTRALIA ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 170 AUSTRALIA ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 171 AUSTRALIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 172 AUSTRALIA ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 173 AUSTRALIA TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 174 AUSTRALIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)
TABLE 175 AUSTRALIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 176 AUSTRALIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 177 AUSTRALIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 178 AUSTRALIA PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 179 THAILAND PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 180 THAILAND EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 181 THAILAND ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 182 THAILAND PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 183 THAILAND OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 184 THAILAND CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 185 THAILAND TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 186 THAILAND MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 187 THAILAND MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 188 THAILAND CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 189 THAILAND INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 190 THAILAND OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 191 THAILAND ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 192 THAILAND ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 193 THAILAND PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 194 THAILAND ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 195 THAILAND TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 196 THAILAND PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)
TABLE 197 THAILAND PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 198 THAILAND PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 199 THAILAND PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 200 THAILAND PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 201 MALAYSIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 202 MALAYSIA EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 203 MALAYSIA ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 204 MALAYSIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 205 MALAYSIA OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 206 MALAYSIA CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 207 MALAYSIA TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 208 MALAYSIA MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 209 MALAYSIA MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 210 MALAYSIA CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 211 MALAYSIA INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 212 MALAYSIA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 213 MALAYSIA ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 214 MALAYSIA ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 215 MALAYSIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 216 MALAYSIA ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 217 MALAYSIA TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 218 MALAYSIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)
TABLE 219 MALAYSIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 220 MALAYSIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 221 MALAYSIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 222 MALAYSIA PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 223 PHILIPPINES PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 224 PHILIPPINES EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 225 PHILIPPINES ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 226 PHILIPPINES PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 227 PHILIPPINES OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 228 PHILIPPINES CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 229 PHILIPPINES TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 230 PHILIPPINES MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 231 PHILIPPINES MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 232 PHILIPPINES CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 233 PHILIPPINES INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 234 PHILIPPINES OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 235 PHILIPPINES ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 236 PHILIPPINES ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 237 PHILIPPINES PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 238 PHILIPPINES ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 239 PHILIPPINES TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 240 PHILIPPINES PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)
TABLE 241 PHILIPPINES PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 242 PHILIPPINES PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 243 PHILIPPINES PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 244 PHILIPPINES PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 245 SINGAPORE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 246 SINGAPORE EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 247 SINGAPORE ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 248 SINGAPORE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 249 SINGAPORE OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 250 SINGAPORE CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 251 SINGAPORE TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 252 SINGAPORE MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 253 SINGAPORE MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 254 SINGAPORE CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 255 SINGAPORE INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 256 SINGAPORE OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 257 SINGAPORE ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 258 SINGAPORE ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 259 SINGAPORE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 260 SINGAPORE ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 261 SINGAPORE TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 262 SINGAPORE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)
TABLE 263 SINGAPORE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 264 SINGAPORE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 265 SINGAPORE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 266 SINGAPORE PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 267 INDONESIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 268 INDONESIA EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 269 INDONESIA ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 270 INDONESIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 271 INDONESIA OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 272 INDONESIA CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 273 INDONESIA TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 274 INDONESIA MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 275 INDONESIA MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 276 INDONESIA CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 277 INDONESIA INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 278 INDONESIA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 279 INDONESIA ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 280 INDONESIA ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 281 INDONESIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 282 INDONESIA ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 283 INDONESIA TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 284 INDONESIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)
TABLE 285 INDONESIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 286 INDONESIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 287 INDONESIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 288 INDONESIA PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 289 VIETNAM PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 290 VIETNAM EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 291 VIETNAM ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 292 VIETNAM PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 293 VIETNAM OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 294 VIETNAM CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 295 VIETNAM TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 296 VIETNAM MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 297 VIETNAM MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 298 VIETNAM CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 299 VIETNAM INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 300 VIETNAM OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 301 VIETNAM ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 302 VIETNAM ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 303 VIETNAM PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 304 VIETNAM ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 305 VIETNAM TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 306 VIETNAM PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)
TABLE 307 VIETNAM PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 308 VIETNAM PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 309 VIETNAM PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 310 VIETNAM PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 311 REST OF ASIA-PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TYPE, 2020-2029 (USD MILLION)
List of Figure
FIGURE 1 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: SEGMENTATION
FIGURE 2 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: DATA TRIANGULATION
FIGURE 3 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: DROC ANALYSIS
FIGURE 4 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: DBMR POSITION GRID
FIGURE 8 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: END USER COVERAGE GRID
FIGURE 10 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: SEGMENTATION
FIGURE 11 NORTH AMERICA IS EXPECTED TO DOMINATE THE ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 INCREASED PREVALENCE OF ORGAN TRANSPLANTATION, RISE IN RECIPIENT PATIENTS, AND PRODUCT APPPROVALS ARE EXPECTED TO DRIVE ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET FROM 2022 TO 2029
FIGURE 13 EPIDEMIOLOGIC EXPOSURE SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET FROM 2022 & 2029
FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR PROPHYLAXIS OF ORGAN REJECTION MANUFACTURERS IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 15 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION: INCIDENCE, 2021
FIGURE 16 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION: INCIDENCE REGIONAL LEVEL, 2021
FIGURE 17 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION: PREVALENCE (2018-2021) AT REGIONAL LEVEL SNAPSHOT
FIGURE 18 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION: SURVIVAL OF PATIENT SNAPSHOT
FIGURE 19 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET
FIGURE 20 INCREASE COUNT OF KIDNEY TRANSPLANTATIONS IN THE U.S., 2020
FIGURE 21 TOTAL NUMBER OF ORGAN TRANSPLANTATION IN THE ASIA PACIFIC SCENARIO, 2020
FIGURE 22 TOTAL NUMBER OF PATIENTS ON WAITING LIST VS TRANSPLANTS PERFORMED BY ORGAN IN 2020
FIGURE 23 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY CAUSE, 2021
FIGURE 24 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY CAUSE, 2020-2029 (USD MILLION)
FIGURE 25 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY CAUSE, CAGR (2022-2029)
FIGURE 26 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY CAUSE, LIFELINE CURVE
FIGURE 27 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY TREATMENT, 2021
FIGURE 28 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY TREATMENT, 2020-2029 (USD MILLION)
FIGURE 29 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY TREATMENT, CAGR (2022-2029)
FIGURE 30 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 31 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 32 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
FIGURE 33 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 34 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 35 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ORGAN, 2021
FIGURE 36 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ORGAN, 2020-2029 (USD MILLION)
FIGURE 37 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ORGAN, CAGR (2022-2029)
FIGURE 38 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ORGAN, LIFELINE CURVE
FIGURE 39 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY PATIENT TYPE, 2021
FIGURE 40 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY PATIENT TYPE, 2020-2029 (USD MILLION)
FIGURE 41 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY PATIENT TYPE, CAGR (2022-2029)
FIGURE 42 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY PATIENT TYPE, LIFELINE CURVE
FIGURE 43 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY END USER, 2021
FIGURE 44 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY END USER, 2020-2029 (USD MILLION)
FIGURE 45 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY END USER, CAGR (2022-2029)
FIGURE 46 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY END USER, LIFELINE CURVE
FIGURE 47 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 48 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
FIGURE 49 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 50 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 51 ASIA-PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: SNAPSHOT (2021)
FIGURE 52 ASIA-PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY COUNTRY (2021)
FIGURE 53 ASIA-PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY COUNTRY (2022 & 2029)
FIGURE 54 ASIA-PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY COUNTRY (2021 & 2029)
FIGURE 55 ASIA-PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY CAUSE (2022-2029)
FIGURE 56 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: COMPANY SHARE 2021 (%)
منهجية البحث
يتم جمع البيانات وتحليل سنة الأساس باستخدام وحدات جمع البيانات ذات أحجام العينات الكبيرة. تتضمن المرحلة الحصول على معلومات السوق أو البيانات ذات الصلة من خلال مصادر واستراتيجيات مختلفة. تتضمن فحص وتخطيط جميع البيانات المكتسبة من الماضي مسبقًا. كما تتضمن فحص التناقضات في المعلومات التي شوهدت عبر مصادر المعلومات المختلفة. يتم تحليل بيانات السوق وتقديرها باستخدام نماذج إحصائية ومتماسكة للسوق. كما أن تحليل حصة السوق وتحليل الاتجاهات الرئيسية هي عوامل النجاح الرئيسية في تقرير السوق. لمعرفة المزيد، يرجى طلب مكالمة محلل أو إرسال استفسارك.
منهجية البحث الرئيسية التي يستخدمها فريق بحث DBMR هي التثليث البيانات والتي تتضمن استخراج البيانات وتحليل تأثير متغيرات البيانات على السوق والتحقق الأولي (من قبل خبراء الصناعة). تتضمن نماذج البيانات شبكة تحديد موقف البائعين، وتحليل خط زمني للسوق، ونظرة عامة على السوق ودليل، وشبكة تحديد موقف الشركة، وتحليل براءات الاختراع، وتحليل التسعير، وتحليل حصة الشركة في السوق، ومعايير القياس، وتحليل حصة البائعين على المستوى العالمي مقابل الإقليمي. لمعرفة المزيد عن منهجية البحث، أرسل استفسارًا للتحدث إلى خبراء الصناعة لدينا.
التخصيص متاح
تعد Data Bridge Market Research رائدة في مجال البحوث التكوينية المتقدمة. ونحن نفخر بخدمة عملائنا الحاليين والجدد بالبيانات والتحليلات التي تتطابق مع هدفهم. ويمكن تخصيص التقرير ليشمل تحليل اتجاه الأسعار للعلامات التجارية المستهدفة وفهم السوق في بلدان إضافية (اطلب قائمة البلدان)، وبيانات نتائج التجارب السريرية، ومراجعة الأدبيات، وتحليل السوق المجدد وقاعدة المنتج. ويمكن تحليل تحليل السوق للمنافسين المستهدفين من التحليل القائم على التكنولوجيا إلى استراتيجيات محفظة السوق. ويمكننا إضافة عدد كبير من المنافسين الذين تحتاج إلى بيانات عنهم بالتنسيق وأسلوب البيانات الذي تبحث عنه. ويمكن لفريق المحللين لدينا أيضًا تزويدك بالبيانات في ملفات Excel الخام أو جداول البيانات المحورية (كتاب الحقائق) أو مساعدتك في إنشاء عروض تقديمية من مجموعات البيانات المتوفرة في التقرير.
